Savara has concluded its Phase I studies of AeroVanc™, which was well-tolerated in healthy volunteers and cystic fibrosis patients and demonstrated an excellent pharmacokinetic profile. We recently completed enrollment on a Phase IIa trial at multiple sites across the U.S.

AeroVanc phase I

Savara has concluded its Phase I studies of AeroVanc™, which was well-tolerated in healthy volunteers and cystic fibrosis patients and demonstrated an excellent pharmacokinetic profile.

 

AeroVanc Phase II

Savara recently completed enrollment on a Phase IIa clinical study of AeroVanc’s safety and efficacy, which was carried out at 40 cystic fibrosis centers throughout the U.S.  Results are expected in Q1-2015.